Assuming monitoring is required, the following results were found.

  • Treating pediatric MS

    and expectations of the child and family, how the drug is expected to control the MS, the side effects, the risks and any monitoring (blood tests, MRI and other tests) after the therapy is started. In this way, providers, patients and families can...

    https://mschristian.org/index.php/blog/treating-pediatric-ms
  • Learn about Neurofilament light polypeptide

    plasma and reflects axonal damage in a wide variety of neurological disorders.[7][8] It is a useful marker for disease monitoring in amyotrophic lateral sclerosis,[9] multiple sclerosis,[10] Alzheimer's disease,[11][12] and more recently Huntington's...

    https://mschristian.org/index.php/blog/learn-about-neurofilament-light-polypeptide
  • Biogen Strengthens MS & SMA Portfolio as Competition Lurks - Yahoo Finance

    two late-stage studies on elenbecestat. The decision was taken following a safety review conducted by the Data Safety Monitoring Board. The board’s recommendation to discontinue the studies was due to unfavorable risk-benefit ratio. In March,...

    https://mschristian.org/index.php/blog/biogen-strengthens-ms-sma-portfolio-as-competition-lurks-yahoo-finance
  • Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies

    ASCLEPIOS are wonderful news for patients who would like to take an effective B-cell therapy with low requirement for monitoring, avoiding visits to an infusion center.” “Ofatumumab, if approved, could be a highly attractive treatment option for a broad...

    https://mschristian.org/index.php/blog/novartis-ofatumumab-demonstrates-superiority-versus-aubagio-in-two-head-to-head-phase-iii-multiple-sclerosis-studies
  • Higher levels of serotonin after a seizure linked to lower incidence of breathing problems

    age of 42. Participants, who had been diagnosed with epilepsy for an average of 17 years, spent time in an epilepsy monitoring unit, where researchers examined one seizure for each participant, evaluating the electrical activity in the brain and the...

    https://mschristian.org/index.php/blog/higher-levels-of-serotonin-after-a-seizure-linked-to-lower-incidence-of-breathing-problems
  • Juul testing new Bluetooth-enhanced ‘lockable’ C1 device in UK market

    Juul C1 e-cigarette pairs with an Android smartphone via Bluetooth to limit who can use it as well as to provide a way of monitoring how often the user vapes, according to an article posted on bbc.com. The product, the first in a series of...

    https://mschristian.org/index.php/blog/juul-testing-new-bluetooth-enhanced-lockable-c1-device-in-uk-market
  • #ECTRIMS2019 - Are Injectables Inappropriate for Active Relapsing MS? - Multiple Sclerosis News Today

    injectables have a “very well-classified” and the best safety profile of all the available treatments for MS, and their monitoring burden is minimal, Zakaria said. With 25 years of experience in the market, they have not been associated with...

    https://mschristian.org/index.php/blog/ectrims2019-are-injectables-inappropriate-for-active-relapsing-ms-multiple-sclerosis-news-today
  • New immunotherapy targeting blood-clotting protein

    Given that the treatment targets an immune response and a blood clotting factor, Akassoglou cautions, however, that tests monitoring the immune system and blood clotting will be important during clinical evaluation. Original link

    https://mschristian.org/index.php/blog/new-immunotherapy-targeting-blood-clotting-protein
  • MS: High-strength MRI may predict disease progression

    that cortical lesions play a key role in the progression of MS, says Mainero, and should be taken into consideration when monitoring those individuals with MS. "We can also use this tool to see how potential treatments can affect the development and...

    https://mschristian.org/index.php/blog/ms-high-strength-mri-may-predict-disease-progression-1
  • Studies Report on Efforts to Optimize Rituximab in MS, NMOSD - The Center for Biosimilars

    Rico A, Boutiere C, et al. Comparison of two individualized administration schemes of rituximab based on memory B cells monitoring in AQP4 positive disorder. Presented at: The 35th Congress of the European Society for Treatment and Research in Multiple...

    https://mschristian.org/index.php/blog/studies-report-on-efforts-to-optimize-rituximab-in-ms-nmosd-the-center-for-biosimilars
  • MS: Paleo diet may reduce fatigue by improving cholesterol

    small sample size, lack of control group, and randomization," they write. "However, if confirmed in larger studies,lipid monitoring may become useful for guiding fatigue treatment decisions," explain Prof. Ramanathan and colleagues. "Fatigue in people...

    https://mschristian.org/index.php/blog/ms-paleo-diet-may-reduce-fatigue-by-improving-cholesterol
  • MSCristian Privacy Notice

    Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the use and satisfaction of this site. If you feel that we are not abiding by this privacy policy, you...

    https://mschristian.org/index.php/articles/site-info/7771-mscristian-privacy-notice
  • Gilenya (fingolimod) FDA approved

    medication in pill form * good safety profile, but some risks require consideration and monitoring * first dose usually give in doctors office * 1:200 risk of eye (macula) swelling * 1:200 risk of symptoms with slow heart rate on first dose * Need to...

    https://mschristian.org/index.php/articles/ms-medications/21-gilenya-fingolimod-fda-approved

Results 1 - 13 of 13
 
 

Follow Us on Twitter

Follow Us On Twitter - Image